Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2021

11 January 2021

Visiongain has published a new report on Pharma Leader Series: Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2021: In-depth Analysis of Top 50 Pharma CMOs: Capabilities, Results, Competition and Sales Potentials.

The global pharmaceutical contract manufacturing market was valued at US$xx billion in 2020 and is projected to reach at a market value of US$xx billion by 2031.

Are you in the global race? Where do you stand in the cut throat global competition?
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.

Bio/Pharmaceutical Manufacturers’ Move Toward Strategic Collaboration With Drug Delivery Technology Companies
Rising healthcare costs, patent cliffs, the highly competitive pharmaceutical market and the need to develop innovative therapies are pushing researchers and market players to search for alternative and new drug delivery technologies. The resulting advanced drug delivery industry is playing a major role in shaping the bio/pharmaceutical industry. Companies with proprietary drug delivery technologies are collaborating with drug manufacturers to apply their technologies to existing products to protect themselves from generic versions and to further develop new drugs. Both the licensing and strategic collaborative business models exist in the drug delivery industry.

Lack of Manufacturing and Packaging Capabilities are Seen as Opportunity by CMOs
Numerous small drug developing companies do not have their own manufacturing facilities and packaging capabilities, so they are dependent upon outsourcing providers for their manufacturing and packaging needs. Halozyme engaged third parties to manufacture bulk rHuPH20, PEGPH20 and Hylenex recombinant. The company has supply agreement

Companies Profiled in the Report
Abbott Lab
AbbVie Contract Manufacturing
Alkermes plc
Aurobindo Pharma Ltd.
Avid Bioservices Inc.
Bavarian Nordic
Baxter Biopharma Solutions
Bayer AG
Becton Dickinson and Co
Boston Scientific
Catalent Pharma Solutions Inc.
Consort Medical plc
CSL Limited
Divi's Laboratories Ltd
Dr reddy lab
Edwards Lifesciences Corp
Eli Lilly and Company
Emergent BioSolutions
Evonik Degussa
F. Hoffmann-La Roche Ltd
Gilead Sciences, Inc.
Huapont Medical
Inovio Pharmaceuticals Inc.
Koninklijke DSM N.V.(Royal DSM)
Lonza AG
McKesson Corporation
Merck & Co.
Merck KGaA
Moderna Biotechnology company
Nipro Corporation
Novartis AG
Novavax Inc.
Novo Nordisk
PPD Inc.
Siemens Healthineers AG
Stryker Corporation
Teva Pharmaceuticals
Thermo Fisher Scientific Inc.
WuXi AppTec
Zhejiang Hisun Pharmaceutical

How this report will benefit you?
The 434-page report provides clear detailed insight into the pharmaceutical contract manufacturing market. Discover the global top 50 rankings, top business strategies adopted by the key players, product mapping, services provided, recent activities of the companies, key drivers and challenges affecting the market.

Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 434-page report you will receive 400+ tables and 300+ figures– all unavailable elsewhere.

Key questions answered by this report:
• Detailed analysis and ranking of top 50 pharma CMOs in the global market
• Current status of market competition, market strategy analysis, product mapping, recent activities
• What is the current size of the total global pharmaceutical contract manufacturing market?
• How much will this market be worth from 2021 to 2031?
• How is the pharmaceutical contract manufacturing market evolving?
• What is driving and restraining the pharmaceutical contract manufacturing market?
• Who are the most prominent companies, and what are their activities and outlooks?
• What are the main trends that will affect the pharmaceutical contract manufacturing market between 2021 and 2031?

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Big Data Analytics in Healthcare Market Report 2021-2031

Healthcare has never been more personalized and affordable to anyone. Digital consulting applications use artificial intelligence to provide medical advice based on customized medical history record reviews and general medical information derived from big data inferences.

13 May 2021


Visiongain Publishes NGS-Based RNA Sequencing Market Report 2021-2031

The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.

11 May 2021


Visiongain Publishes Single-Use Bioreactors Market Report 2021-2031

Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.

11 May 2021


Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021